Kyle Tynan joined NIST in 2024 as an NRC Postdoctoral researcher. Kyle received his Ph.D. from Carnegie Mellon University in chemical engineering
His research activities at NIST focus on developing novel analytical techniques to improve the characterization, quality, and standardization of nucleic acid therapeutics. His current work includes advancing analytical approaches for the characterization of dsRNA impurities in in vitro transcribed mRNA, investigating protein corona formation on mRNA lipid nanoparticles, and developing reference materials to support the RNA therapeutics community.